Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk
NCT00192439 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500
Last updated 2007-05-07
Summary
\- Estimate the incidence rate of hMPV infection detected by RT-PCR from frozen nasal wash aspirates in children at high risk for severe LRI disease (hospitalized at \<2 years of age).
Conditions
- Severe Respiratory Disease
Interventions
- BEHAVIORAL
-
High Risk Respiratory Disease
Sponsors & Collaborators
-
MedImmune LLC
lead INDUSTRY
Principal Investigators
-
Margarita Gomez, M.D. · MedImmune LLC
Eligibility
- Min Age
- 1 Day
- Max Age
- 24 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-12-31
- Completion
- 2006-12-31
Countries
- United States
- Australia
- Canada
- Italy
Study Locations
More Related Trials
-
A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
NCT03982199 ·Status: TERMINATED ·Phase: PHASE2
-
Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers
NCT02484417 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children
NCT04484935 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
NCT06237296 ·Status: COMPLETED ·Phase: PHASE1
-
Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age
NCT01754428 ·Status: COMPLETED
-
Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children
NCT01459198 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
NCT02298179 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
NCT00686075 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
NCT00500578 ·Status: COMPLETED ·Phase: PHASE4
-
RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
NCT00632463 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
NCT05842967 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness
NCT00421304 ·Status: COMPLETED ·Phase: NA
-
Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine
NCT02419391 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)
NCT03979313 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
NCT04908683 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
NCT03227029 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
NCT00493285 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
NCT04909021 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT01968083 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children
NCT04444284 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults
NCT04227210 ·Status: COMPLETED ·Phase: PHASE1
-
Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
NCT00593918 ·Status: COMPLETED
-
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
NCT05743881 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection
NCT00192504 ·Status: COMPLETED ·Phase: PHASE1
-
The Development of a Human Model of Respiratory Syncytial Virus Infection
NCT01349543 ·Status: COMPLETED ·Phase: NA